Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor Europe
UK
7+ years of experience
Scrip
By Kevin Grogan 16 Nov 2021
Having strongly made the case for Jardiance as a treatment for chronic heart failure, Boehringer Ingelheim and Eli Lilly believe the SGLT2 inhibitor could have a lot of potential in acute heart failure as well after promising data from the EMPULSE study.
Scrip
By Kevin Grogan 21 Jul 2021
Sales at the Swiss major have returned to around 80%-90% of their pre-pandemic levels, according to CFO Harry Kirsch after unveiling a healthy set of second-quarter financials.
Scrip
By Kevin Grogan 22 Jun 2021
Koselugo (selumetinib) was largely forgotten after failing Phase III trials in thyroid and lung cancer, as well as uveal melanoma, but its approval in Europe for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, which follows a US approval for the rare condition last year, has breathed new life into the once-lauded MEK 1/2 inhibitor.
Scrip
By Kevin Grogan 04 May 2021
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
Scrip
By Kevin Grogan 07 Apr 2021
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Scrip
By Kevin Grogan 23 Mar 2021
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.
Scrip
By Kevin Grogan 27 Nov 2020
As the coronavirus spreads beyond China, biopharma companies are taking precautions, with some more wary than others.
Topic China Coronavirus
Scrip
By Kevin Grogan 27 Nov 2020
As Biogen moves to file its controversial amyloid drug aducanumab for approval in the US, two similar investigational Alzheimer's drugs – Eli Lilly's solanezumab and Roche's gantenerumab – did not slow memory loss or cognitive decline in a rare, inherited form of the disease.
Topic Alzheimer's Disease
Scrip
By Kevin Grogan 01 Jun 2020
Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.
Topic Coronavirus
Scrip
By Kevin Grogan 01 May 2020
Vas Narasimhan hopes that donations and the "unprecedented collaborations" between drugmakers trying to overcome the COVID-19 pandemic is leading to a shift in the perception of the value of the sector to society.
Topic Coronavirus Leadership Strategy
Scrip
By Kevin Grogan 30 Apr 2020
Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.
Topic Coronavirus Sales Earnings
Scrip
By Kevin Grogan 07 Feb 2020
The pharma major is providing its adjuvant system, designed to enhance the body’s immune response, to help the Coalition for Epidemic Preparedness Innovations' efforts to accelerate the creation of a vaccine for the coronavirus strain that broke out in China and has spread to 24 countries.
Topic Coronavirus
Scrip
By Kevin Grogan 20 Nov 2019
The former GlaxoSmithKline CEO has given his views on the prospects for healthcare systems, saying that intelligently applying digital technologies can lead to simpler, more cost-effective health systems.
Topic Digital Health
Scrip
By Kevin Grogan 23 Oct 2019
Ketamine-Like Antidepressant Backed By CHMP If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
Scrip
By Kevin Grogan 13 Jun 2019
Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.
Topic Business Strategies Strategy
Scrip
21 Jul 2022
Scrip
21 Jul 2022
Scrip
20 Jul 2022
Scrip
20 Jul 2022
Scrip
19 Jul 2022
Scrip
19 Jul 2022
Scrip
18 Jul 2022
Scrip
18 Jul 2022
Scrip
14 Jul 2022
Scrip
14 Jul 2022
Scrip
13 Jul 2022
Scrip
13 Jul 2022
Scrip
12 Jul 2022
Scrip
12 Jul 2022
Scrip
11 Jul 2022
